Trial · NCT01876784
Results by group19
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 19 of 19
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-Free Survival (PFS) | Randomized Treatment Period: Vandetanib | 10.0 | 95% Confidence Interval 6.0 to 11.1 | months | |
| Progression-Free Survival (PFS) | Randomized Treatment Period: Placebo | 5.7 | 95% Confidence Interval 5.5 to 8.4 | months | |
| Overall Survival (OS) | Vandetanib/Vandetanib | NA | 95% Confidence Interval 31.6 to NA | months | |
| Overall Survival (OS) | Placebo/Vandetanib | NA | 95% Confidence Interval 32.1 to NA | months | |
| Randomized Treatment Period: Percent Change From Baseline in Tumor Size (TS) at Week 36 | Randomized Treatment Period: Vandetanib | 23.29 | Standard Deviation 50.059 | percent change | |
| Randomized Treatment Period: Percent Change From Baseline in Tumor Size (TS) at Week 36 | Randomized Treatment Period: Placebo | 21.52 | Standard Deviation 25.428 | percent change | |
| Percentage of Participants With Objective Response | Vandetanib/Vandetanib | 5.0 | percentage of participants | ||
| Percentage of Participants With Objective Response | Placebo/Vandetanib | 0 | percentage of participants | ||
| Time to Worsening of Pain (TWP) Using Numeric Rating Scale (NRS) of Worst Pain | Vandetanib/Vandetanib | 5.6 | 95% Confidence Interval 2.9 to 8.4 | months | |
| Time to Worsening of Pain (TWP) Using Numeric Rating Scale (NRS) of Worst Pain | Placebo/Vandetanib | 8.3 | 95% Confidence Interval 2.8 to 16.6 | months | |
| Duration of Response (DOR) | Vandetanib/Vandetanib | NA | 95% Confidence Interval NA to NA | months | |
| Randomized Treatment Period: PK Parameters: Maximum Plasma Concentration (Cmax) | Randomized Treatment Period: Vandetanib | Week 1 | 695.1 | Standard Deviation 238.94 | ng/ml |
| Randomized Treatment Period: PK Parameters: Maximum Plasma Concentration (Cmax) | Randomized Treatment Period: Vandetanib | Week 2 | 846.2 | Standard Deviation 288.98 | ng/ml |
| Randomized Treatment Period: PK Parameters: Maximum Plasma Concentration (Cmax) | Randomized Treatment Period: Vandetanib | Week 4 | 975.7 | Standard Deviation 358.33 | ng/ml |
| Randomized Treatment Period: PK Parameters: Maximum Plasma Concentration (Cmax) | Randomized Treatment Period: Vandetanib | Week 8 | 1043.1 | Standard Deviation 395.08 | ng/ml |
| Randomized Treatment Period: PK Parameters: Maximum Plasma Concentration (Cmax) | Randomized Treatment Period: Vandetanib | Week 12 | 1041.9 | Standard Deviation 404.69 | ng/ml |
| Randomized Treatment Period: PK Parameters: Maximum Plasma Concentration (Cmax) | Randomized Treatment Period: Vandetanib | Week 24 | 1004.9 | Standard Deviation 408.34 | ng/ml |
| Randomized Treatment Period: PK Parameters: Maximum Plasma Concentration (Cmax) | Randomized Treatment Period: Vandetanib | Week 36 | 904.1 | Standard Deviation 312.51 | ng/ml |
| Randomized Treatment Period: PK Parameters: Maximum Plasma Concentration (Cmax) | Randomized Treatment Period: Vandetanib | Week 48 | 963.0 | Standard Deviation 452.4 | ng/ml |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01876784/results